Evaluation of recombinant A/Victoria/3/75 (H3N2) influenza neuraminidase mutants as potential broad-spectrum subunit vaccines against influenza A

Archives of Virology

Volumn 143, Issue 10, 1998, Pages 2011-2019

  Martinet, W ^a   Deroo, T ^a   Saelens, X ^a   Beirnaert, E ^b   Vanlandschoot, P ^c   Contreras, R ^a   Fiers, W ^a   Min Jou, W ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SUBSTITUTION; ANTIGEN STRUCTURE; ENZYME STRUCTURE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A; RECOMBINANT ENZYME; SIALIDASE; TARGETED MUTAGENESIS; VACCINATION;

ANIMALS; CROSS REACTIONS; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; NEURAMINIDASE; SPODOPTERA; VACCINES, SYNTHETIC;

ANIMALIA; VICTORIA;

EID: 0031732384     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007050050437     Document Type: Article

References (22)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
2. Cataldo DM, Van Nest G (1997) The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15: 1 710-1 715
3. Deroo T, Min Jou W, Fiers W (1996) Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 14: 561-569
4. Gruber WC, Belshe RB, King JC, Treanor JJ, Piedra PA, Wright PF, Reed GW, Anderson E, Newman F (1996) Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 173: 1 313-1 319
5. Martinet W, Saelens X, Deroo T, Neirynck S, Contreras R, Min Jou W, Fiers W (1997) Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur J Biochem 247: 332-338
6. Monto AS, Ohmit SE (1996) Effectiveness evaluation of inactivated influenza vaccines: methods and results. In: Options for the control of influenza III. Proceedings of the third international conference on options for the control of influenza. Cairns 1996, Elsevier Science BV, Amsterdam, pp 93-96
7. Morinaga Y, Franceschini T, Inouye S, Inouye M (1984) Improvement of oligonucleotide-directed site-specific mutagenesis using double stranded plasmid DNA. Bio/Technology 2: 636-639
8. Nuss JM, Whitaker PB, Air GM (1993) Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase. Proteins Struct Funct Genet 15: 121-132
9. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67: 2 552-2558
10. Okuno Y, Matsumoto K-I, Isegawa Y, Ueda S (1994) Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 68: 517-520
11. Parkin NT, Chiu P, Coelingh K (1997) Genetically engineered live attenuated influenza A virus vaccine candidates. J Virol 71: 2 772-2 778
12. Potier M, Mameli L, Bélisle M, Dallaire L, Melançon SB (1979) Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetylneuraminate) substrate. Anal Biochem 94: 287-296
13. Powers DC, Smith GE, Anderson EL, Kennedy DJ, Hackett CS, Wilkinson BE, Volvovitz F, Belshe, RB, Treanor JJ (1995) Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 171: 1 595-1 599
14. Saito T, Taylor G, Webster R (1995) Steps in maturation of influenza A virus neuraminidase. J Virol 69: 5 011-5 017
15. Schoenbaum SC (1996) Impact of influenza in persons and populations. In: Options for the control of influenza III. Proceedings of the third international conference on options for the control of influenza, Cairns 1996. Elsevier Science BV, Amsterdam, pp 17-25
16. Szucs TD (1996) The economic impact of influenza in Europe. In: Options for the control of influenza III. Proceedings of the third international conference on options for the control of influenza, Cairns 1996. Elsevier Science BV, Amsterdam, pp 34-42
17. Tulip WR, Harley VR, Webster RG, Novotny J (1994) N9 neuraminidase complexes with antibodies NC41 and NC10: empirical free energy calculations capture specificity trends observed with mutant binding data. Biochemistry 33: 7 986-7 997
18. Vanlandschoot P, Beirnaert E, Dewilde S, Saelens X, Bestebroer T, De Jong J, Min Jou W, Fiers W (1995) A fairly conserved epitope on the hemagglutinin of influenza A (H3N2) virus with variable accessibility to neutralizing antibody. Virology 212: 526-534
19. Vanlandschoot P, Maertens G, Min Jou W, Fiers W (1993) Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. Vaccine 11: 1 185-1 187
20. Varghese JN, Colman PM (1991) Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 Å resolution. J Mol Biol 221: 473-486
21. Varghese JN, Laver WG, Colman PM (1983) Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 303: 35-40
22. Xu X, Cox NJ, Bender CA, Regnery HL, Shaw MW (1996) Genetic variation in neuraminidase genes of influenza A (H3N2) viruses. Virology 224: 175-183